Table of Contents
MUMBAI, India — Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for adapalene and benzoyl peroxide gel, 0.1% 2.5%, the generic version of Epiduo Gel, 0.1% 2.5%, of Galderma Laboratories.
According to IQVIA sales data for the 12 month period ending September 2019, the Epiduo Gel, 0.1%|2.5% market2 achieved annual sales of approximately $33.7 million.
Glenmark’s current portfolio consists of 163 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
